car-t

Addition to the Conditional Monge Gap to extend it to Chimeric Antigen Receptor T cell scRNAseq data

Files and code used to generate the CARTAR app to identify and validate CAR targets for cancer treatment.

Systematic pipeline for identifying combinatorial CAR-T targets in acute myeloid leukemia (AML) using single-cell RNA-seq data

Single-cell transcriptomic profiling of CAR T cells expressing synthetic receptors, termed "velocity CAR T" cells.

Files and code used to generate the CARTAR app to identify and validate CAR targets for cancer treatment.

Interactive dashboard tracking CAR-T, CAR-NK, CAAR-T, and CAR-γδ T clinical trials across heme- and solid-onc from ClinicalTrials.gov v2. Sister app to Rheumatology-CAR-T-Trials-Monitor.

Single-cell analysis of CAR T-cell therapy responses, identifying cellular signatures and pathways associated with treatment outcomes.

Quantitative analysis of single-cell CAR-T and TIL killing kinetics from microwell co-culture imaging: EM mixture models for per-well kill rate, predator-prey ODE fits, and single-effector-cell statistics

R analysis of xCELLigence real-time impedance killing assays for T/CAR-cell and NK cytotoxicity

Personalized lymphoma therapy design with Gemma 4, AlphaFold, RFdiffusion. Kaggle Gemma 4 Good Hackathon submission.

Cell Design Labs — independent third-party profile of a public API surface, by API Evangelist. Cell Design Labs, Inc. was a biotherapeutics company based at 5858 Horton Street, Emeryville, California, that engineered immune cells into "smart, living therapies" for cancer and other diseases.

AbelZeta Pharma — independent third-party profile of a public API surface, by API Evangelist. AbelZeta Pharma is a global clinical-stage cell therapy company discovering, developing, and manufacturing T-cell-based immunotherapeutics for cancer and immunological diseases. Its pipeline centers on Chimeric Antigen Receptor (CAR)-T cell technology acro

Orbital Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Orbital Therapeutics was a Cambridge, Massachusetts biotechnology company developing next-generation RNA medicines, combining circular and linear RNA, targeted delivery, and AI-guided design across immunomodulation, in vivo CAR-T cell therapy, next-ge

Umoja Biopharma — independent third-party profile of a public API surface, by API Evangelist. Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of tra

Repository for analyses of HHV-6 reactivation using genomics

Kyverna Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company headquartered in Emeryville, California, developing engineered T cell therapies for patients suffering from autoimmune diseases.

Autolus * — independent third-party profile of a public API surface, by API Evangelist. Autolus is a life-sciences (biopharmaceutical) company operating in the cell-therapy space, developing programmed / engineered T cell (CAR-T) therapies for cancer and other serious diseases. It was surfaced as a portfolio company of GV and added to the API Evang

oricell — independent third-party profile of a public API surface, by API Evangelist. Oricell Therapeutics (原启生物) is a Shanghai-based clinical-stage biopharmaceutical company developing cell-based immunotherapies for cancer, including GPC3-targeted CAR-T (Ori-C101) for advanced liver cancer and GPRC5D-targeted CAR-T (OriCAR-017) for relapsed/refrac

Using scRNA-seq, machine learning, and online datasets to find candidate target antigens for repurposing CAR T-cell therapy for autoimmune diseases.

Link Cell Therapies — independent third-party profile of a public API surface, by API Evangelist. Link Cell Therapies is a South San Francisco clinical-stage cell therapy company founded by Stanford investigators Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital, working on the development of safe and effective CAR T agents